Hanmi Science Co., Ltd. (KRX:008930)

Market Cap	2.61T +41.2%
Revenue (ttm)	1.36T +5.7%
Net Income	118.37B +99.2%
EPS	1,747.00 +99.0%
Shares Out	67.71M
PE Ratio	22.07
Forward PE	n/a
Dividend	400.00 (1.05%)
Ex-Dividend Date	Mar 30, 2026

Volume	160,434
Average Volume	139,801
Open	39,300
Previous Close	38,000
Day's Range	37,850 - 39,700
52-Week Range	24,300 - 55,500
Beta	0.71
RSI	50.35
Earnings Date	Apr 28, 2026

About Hanmi Science

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult’s bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1973
• Employees: 476
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 008930

Financial Performance

In 2025, Hanmi Science's revenue was 1.36 trillion, an increase of 5.73% compared to the previous year's 1.28 trillion. Earnings were 118.37 billion, an increase of 99.20%.